MADRIGAL PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $20.00K, a 99.50% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $1.67M.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $3.98M.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $583.00K, a 55.05% increase from fiscal 2021.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $376.00K, a 16.63% decline from fiscal 2020.
- MADRIGAL PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $451.00K, a 49.89% decline from fiscal 2019.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 1 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 2 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $1.69M 10-Q · filed 2026-07-30 | $1.69M derived: sum of 3 quarters · filed 2026-07-30 | $1.69M derived: sum of 4 quarters · filed 2026-07-30 | |||||
| 2026-03-31 | $1.67M 10-Q · filed 2026-05-06 | $1.67M derived: sum of 2 quarters · filed 2026-05-06 | $1.67M derived: sum of 3 quarters · filed 2026-05-06 | $5.65M derived: sum of 4 quarters · filed 2026-07-30 | |||||
| 2026-03-01 | $1.40M 10-Q · filed 2026-07-30 | ||||||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $3.98M derived: sum of 3 quarters · filed 2026-07-30 | $3.98M 10-K · filed 2026-02-19 | |||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.98M derived: sum of 2 quarters · filed 2026-07-30 | $3.98M 10-Q · filed 2025-11-04 | $4.11M derived: sum of 4 quarters · filed 2026-07-30 | |||||
| 2025-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $3.98M 10-Q · filed 2026-07-30 | $4.11M derived: sum of 3 quarters · filed 2026-07-30 | $5.31M derived: sum of 4 quarters · filed 2026-07-30 | |||||
| 2025-05-31 | $4.00M 10-Q · filed 2026-07-30 | ||||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $1.20M 10-Q · filed 2025-05-01 | $132.00K derived: sum of 2 quarters · filed 2026-07-30 | $1.33M derived: sum of 3 quarters · filed 2026-07-30 | |||||
| 2024-12-31 | $200.00K 10-Q · filed 2025-08-05 | $132.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | $1.33M derived: sum of 2 quarters · filed 2026-07-30 | $1.30M 10-Q · filed 2026-07-30 | $1.33M 10-K · filed 2025-02-26 | ||||
| 2024-10-31 | $200.00K 10-K · filed 2025-02-26 | ||||||||
| 2024-09-30 | $1.20M 10-Q · filed 2025-08-05 | $1.20M 10-Q · filed 2024-10-31 | $1.17M 10-Q · filed 2025-11-04 | ||||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | ||||||||
| 2024-05-31 | $1.20M 10-K · filed 2025-02-26 | ||||||||
| 2023-12-31 | -$28.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-30 | $1.60M derived: sum of 2 quarters · filed 2026-07-30 | $1.60M 10-Q · filed 2026-07-30 | $1.63M 10-K · filed 2024-02-28 | |||||
| 2023-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.63M 10-Q · filed 2024-10-31 | |||||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | ||||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $583.00K 10-K · filed 2025-02-26 | ||||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $583.00K 10-Q · filed 2023-11-06 | |||||||
| 2022-06-30 | $583.00K 10-Q · filed 2023-08-08 | ||||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $376.00K 10-K · filed 2024-02-28 | ||||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $376.00K 10-Q · filed 2022-11-03 | |||||||
| 2021-06-30 | $376.00K 10-Q · filed 2022-08-04 | ||||||||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $451.00K derived: sum of 2 quarters · filed 2023-03-03 | $451.00K derived: sum of 3 quarters · filed 2023-03-03 | $451.00K 10-K/A · filed 2023-03-03 | |||||
| 2020-09-30 | $451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $451.00K derived: sum of 2 quarters · filed 2021-11-04 | $451.00K 10-Q · filed 2021-11-04 | $451.00K derived: sum of 4 quarters · filed 2022-02-24 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 | |||||
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $0.00 derived: sum of 4 quarters · filed 2022-02-24 | |||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $0.00 derived: sum of 2 quarters · filed 2022-02-24 | $0.00 derived: sum of 3 quarters · filed 2022-02-24 | $900.00K 10-K · filed 2022-02-24 | |||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $900.00K 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $900.00K 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | $900.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |